A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non-small cell lung cancer.
暂无分享,去创建一个
C. Schumann | Michael Thomas | J. Bosch-Barrera | L. Paz-Ares | K. Dalhoff | E. Calvo | M. Sebastian | A. Bence Lin | N. Dickgreber | T. Wehler | K. Hurt | S. Hynes | N. Viñolas Segarra | J. Corral Jaime | Ji Lin | M. Alonso